Amino acid transporter-targeted radiotracers for molecular imaging in oncology

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3271-3281

  Kong, Fan Lin ^a   Yang, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Amino acid transporter; Cancer diagnosis; Molecular imaging; Positron emission tomography; Radiotracer; Single photon emission computed tomography

Indexed keywords

2 FLUOROTYROSINE F 18; 3 FLUORO ALPHA METHYLTYROSINE F 18; 3 IODOMETIROSINE I 131; 5 HYDROXYTRYPTOPHAN C 11; 6 FLUORODOPA F 18; AMINO ACID TRANSPORTER; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; METHIONINE TC 99M; METHYLMETHIONINE C 11; N,N' ETHYLENE DICYSTEINE ALPHA METHYLTYROSINE TC 99M; O 2 FLUOROETHYLTYROSINE F 18; SOMATOSTATIN RECEPTOR; TRACER; TYROSINE C 11; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; BENIGN TUMOR; BRAIN TUMOR; CANCER PROGNOSIS; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG SYNTHESIS; DRUG UPTAKE; FLUORINATION; GLIOBLASTOMA; GLIOMA; GOLD STANDARD; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXILLOFACIAL DISORDER; MOLECULAR IMAGING; MOUTH SQUAMOUS CELL CARCINOMA; MUSCULOSKELETAL DISEASE; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET CELL TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RADIOACTIVITY; RADIOCHEMISTRY; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL;

AMINO ACID TRANSPORT SYSTEMS; AMINO ACIDS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; HUMANS; MOLECULAR IMAGING; NEOPLASMS; RADIOACTIVE TRACERS;

EID: 84863738723     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215946     Document Type: Review

References (105)

1. Gustav K. von Schulthess, M., PhD, Molecular Anatomic Imaging: PET-CT and SPECT-CT Integrated Modality. 2nd ed. 2007.
2. Delbeke, D., R.E. Coleman, M.J. Guiberteau, M.L. Brown, H.D. Royal, B.A. Siegel, D.W. Townsend, L.L. Berland, J.A. Parker, K. Hubner, M.G. Stabin, G. Zubal, M. Kachelriess, V. Cronin, and S. Holbrook, Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med, 2006. 47(5): p. 885-95.
3. Strauss, L.G., Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology. Oncologist, 1997. 2(6): p. 381-388.
4. Chang, J.M., H.J. Lee, J.M. Goo, H.Y. Lee, J.J. Lee, J.K. Chung, and J.G. Im, False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol, 2006. 7(1): p. 57-69.
5. Rosenbaum, S.J., T. Lind, G. Antoch, and A. Bockisch, False-positive FDG PET uptake-the role of PET/CT. Eur Radiol, 2006. 16(5): p. 1054-65.
6. Sundin, A., B. Eriksson, M. Bergstrom, B. Langstrom, K. Oberg, and H. Orlefors, PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci, 2004. 1014: p. 246-57.
7. Ganapathy, V., M. Thangaraju, and P.D. Prasad, Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther, 2009. 121(1): p. 29-40.
8. Shikano N, Kubota N., Ishikawa N, Molecular biology of L-type amino acid transporters. Acta Scientiarvm Valetvdinis Universitatis Praefectvralis Ibarakiensis, 2002. 7: p. 21-32.
9. Johnstone, R.M. and P.G. Scholefield, Amino acid transport in tumor cells. Adv Cancer Res, 1965. 9: p. 143-226.
10. Souba, W. W. and A.J. Pacitti, How amino acids get into cells: mechanisms, models, menus, and mediators. JPEN J Parenter Enteral Nutr, 1992. 16(6): p. 569-78.
11. Christensen, H.N., Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev, 1990. 70(1): p. 43-77.
12. Closs, E.I., J.P. Boissel, A. Habermeier, and A. Rotmann, Structure and function of cationic amino acid transporters (CATs). J Membr Biol, 2006. 213(2): p. 67-77.
13. Castagna, M., C. Shayakul, D. Trotti, V.F. Sacchi, W.R. Harvey, and M.A. Hediger, Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis. J Exp Biol, 1997. 200(Pt 2): p. 269-86.
14. MacLeod, C.L., K.D. Finley, and D.K. Kakuda, y(+)-type cationic amino acid transport: expression and regulation of the mCAT genes. J Exp Biol, 1994. 196: p. 109-21.
15. Busch, H., J.R. Davis, G.R. Honig, D.C. Anderson, P. V. Nair, and W.L. Nyhan, The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res, 1959. 19: p. 1030-9.
16. Isselbacher, K.J., Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med, 1972. 286(17): p. 929-33.
17. Jager, P.L., W. Vaalburg, J. Pruim, E.G. de Vries, K.J. Langen, and D.A. Piers, Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med, 2001. 42(3): p. 432-45.
18. Langen, K.J. and S. Broer, Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. J Nucl Med, 2004. 45(9): p. 1435-6.
19. McGivan, J.D. and M. Pastor-Anglada, Regulatory and molecular aspects of mammalian amino acid transport. Biochem J, 1994. 299 (Pt 2): p. 321-34.
20. Kondoh, N., N. Imazeki, M. Arai, A. Hada, K. Hatsuse, H. Matsuo, O. Matsubara, S. Ohkura, and M. Yamamoto, Activation of a system A amino acid transporter, A TA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol, 2007. 31(1): p. 81-7.
21. Kaira, K., N. Oriuchi, H. Imai, K. Shimizu, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, Y. Kanai, H. Endou, T. Nakajima, and M. Mori, Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci, 2008.
22. Yanagida, O., Y. Kanai, A. Chairoungdua, D.K. Kim, H. Segawa, T. Nii, S.H. Cha, H. Matsuo, J. Fukushima, Y. Fukasawa, Y. Tani, Y. Taketani, H. Uchino, J.Y. Kim, J. Inatomi, I. Okayasu, K. Miyamoto, E. Takeda, T. Goya, and H. Endou, Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta, 2001. 1514(2): p. 291-302.
23. Kaira, K., N. Oriuchi, H. Imai, K. Shimizu, N. Yanagitani, N. Sunaga, T. Hisada, O. Kawashima, H. Iijima, T. Ishizuka, Y. Kanai, H. Endou, T. Nakajima, and M. Mori, Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract, 2008. 204(8): p. 553-61.
24. Nawashiro, H., N. Otani, N. Shinomiya, S. Fukui, H. Ooigawa, K. Shima, H. Matsuo, Y. Kanai, and H. Endou, L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer, 2006. 119(3): p. 484-92.
25. Uchino, H., Y. Kanai, D.K. Kim, M.F. Wempe, A. Chairoungdua, E. Morimoto, M.W. Anders, and H. Endou, Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol, 2002. 61(4): p. 729-37.
26. Kim, C.S., S.H. Cho, H.S. Chun, S.Y. Lee, H. Endou, Y. Kanai, and K. Kim do, BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull, 2008. 31(6): p. 1096-100.
27. McConathy, J. and M.M. Goodman, Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev, 2008. 27(4): p. 555-73.
28. Langstrom, B., G. Antoni, P. Gullberg, C. Halldin, P. Malmborg, K. Nagren, A. Rimland, and H. Svard, Synthesis of L-and D-[methyl-11C]methionine. J Nucl Med, 1987. 28(6): p. 1037-40.
29. Lodi, F., A. Rizzello, S. Trespidi, D. Di Pierro, M. Marengo, M. Farsad, S. Fanti, A. Al-Nahhas, D. Rubello, and S. Boschi, Reliability and reproducibility of N-[11C]methyl-choline and L-(S-methyl-[11C])methionine solid-phase synthesis: a useful and suitable method in clinical practice. Nucl Med Commun, 2008. 29(8): p. 736-40.
30. Singhal, T., T.K. Narayanan, V. Jain, J. Mukherjee, and J. Mantil, 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol, 2008. 10(1): p. 1-18.
31. Kracht, L.W., H. Miletic, S. Busch, A.H. Jacobs, J. Voges, M. Hoevels, J.C. Klein, K. Herholz, and W.D. Heiss, Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res, 2004. 10(21): p. 7163-70.
32. Herholz, K., T. Holzer, B. Bauer, R. Schroder, J. Voges, R.I. Ernestus, G. Mendoza, G. Weber-Luxenburger, J. Lottgen, A. Thiel, K. Wienhard, and W.D. Heiss, 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology, 1998. 50(5): p. 1316-22.
33. Ceyssens, S., K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans, [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol, 2006. 27(7): p. 1432-7.
34. Cook, G.J., M.N. Maisey, and I. Fogelman, Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med, 1999. 26(10): p. 1363-78.
35. Pruim, J., A.T. Willemsen, W.M. Molenaar, A. van Waarde, A.M. Paans, M.A. Heesters, K.G. Go, G.M. Visser, E.J. Franssen, and W. Vaalburg, Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology, 1995. 197(1): p. 221-6.
36. Kole, A.C., O.E. Nieweg, J. Pruim, A.M. Paans, J.T. Plukker, H.J. Hoekstra, H. Schraffordt Koops, and W. Vaalburg, Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11 C]tyrosine PE T. J Nucl Med, 1997. 38(5): p. 692-6.
37. de Boer, J.R., J. Pruim, B.F. van der Laan, T.H. Que, A.T. Willemsen, F.W. Albers, and W. Vaalburg, L-1-11C-tyrosine PET in patients with laryngeal carcinomas: comparison of standardized uptake value and protein synthesis rate. J Nucl Med, 2003. 44(3): p. 341-6.
38. Plaat, B., A. Kole, M. Mastik, H. Hoekstra, W. Molenaar, and W. Vaalburg, Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med, 1999. 26(4): p. 328-32.
39. Halldin, C., K.O. Schoeps, S. Stone-Elander, and F.A. Wiesel, The Bucherer-Strecker synthesis of D-and L-(1-11C)tyrosine and the in vivo study of L-(1-11C)tyrosine in human brain using positron emission tomography. Eur J Nucl Med, 1987. 13(6): p. 288-91.
40. Bjurling, P., G. Antoni, Y. Watanabe, and B. Langstrom, Enzymatic-Synthesis of Carboxy-C-11-Labeled L-Tyrosine, L-Dopa, L-Tryptophan and 5-Hydroxy-L-Tryptophan. Acta Chemica Scandinavica, 1990. 44(2): p. 178-182.
41. Luurtsema, G., J. Medema, P.H. Elsinga, G.M. Visser, and W. Vaalburg, Robotic Synthesis of L-[1-C-11]Tyrosine. Applied Radiation and Isotopes, 1994. 45(8): p. 821-828.
42. Braams, J.W., J. Pruim, P.G. Nikkels, J.L. Roodenburg, W. Vaalburg, and A. Ve rme y, Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med, 1996. 37(6): p. 897-901.
43. Daemen, B.J., R. Zwertbroek, P.H. Elsinga, A.M. Paans, H. Doorenbos, and W. Vaalburg, PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment. Eur J Nucl Med, 1991. 18(7): p. 453-60.
44. Kole, A.C., B.E. Plaat, H.J. Hoekstra, W. Vaalburg, and W.M. Molenaar, FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med, 1999. 40(3): p. 381-6.
45. de Boer, J.R., J. Pruim, F. W. Albers, F. Burlage, W. Vaalburg, and B.F. van der Laan, Prediction of survival and therapy outcome with 11C-tyrosine PET in patients with laryngeal carcinoma. J Nucl Med, 2004. 45(12): p. 2052-7.
46. Kole, A.C., H.J. Hoekstra, D.T. Sleijfer, O.E. Nieweg, H. Schraffordt Koops, and W. Vaalburg, L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ-cell tumors. J Nucl Med, 1998. 39(6): p. 1027-9.
47. Neels, O.C., K.P. Koopmans, P.L. Jager, L. Vercauteren, A. van Waarde, J. Doorduin, H. Timmer-Bosscha, A.H. Brouwers, E.G. de Vries, R.A. Dierckx, I.P. Kema, and P.H. Elsinga, Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3, 4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res, 2008. 68(17): p. 7183-90.
48. Neels, O.C., P.L. Jager, K.P. Koopmans, E. Eriks, E.G.E. de Vries, I.P. Kema, and P.H. Elsinga, Develoment of a reliable remote-controlled synthesis of beta-[C-11]-5-hydroxy-L-tryptophan on a Zymark robotic system. Journal of Labelled Compounds & Radiopharmaceuticals, 2006. 49(10): p. 889-895.
49. Orlefors, H., A. Sundin, U. Garske, C. Juhlin, K. Oberg, B. Skogseid, B. Langstrom, M. Bergstrom, and B. Eriksson, Whole-body C-11-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. Journal of Clinical Endocrinology & Metabolism, 2005. 90(6): p. 3392-3400.
50. Koopmans, K.P., O.C. Neels, I.P. Kema, P.H. Elsinga, W.J. Sluiter, K. Vanghillewe, A.H. Brouwers, P.L. Jager, and E.G.E. de Vries, Improved staging of patients with carcinoid and islet cell tumors with F-18-dihydroxy-phenyl- alanine and C-11-5-hydroxy-tryptophan positron emission tomography. Journal of Clinical Oncology, 2008. 26(9): p. 1489-1495.
51. Coenen, H.H., P. Kling, and G. Stocklin, Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med, 1989. 30(8): p. 1367-72.
52. Wienhard, K., K. Herholz, H.H. Coenen, J. Rudolf, P. Kling, G. Stocklin, and W.D. Heiss, Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med, 1991. 32(7): p. 1338-46.
53. Hustinx, R., C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.F. Fassotte, J. Foidart, and A. Luxen, Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. J Nucl Med, 2003. 44(4): p. 533-9.
54. Inoue, T., T. Shibasaki, N. Oriuchi, K. Aoyagi, K. Tomiyoshi, S. Amano, M. Mikuni, I. Ida, J. Aoki, and K. Endo, 18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med, 1999. 40(3): p. 399-405.
55. Urakami, T., K. Sakai, T. Asai, D. Fukumoto, H. Tsukada, and N. Oku, Evaluation of O-[(18)F]fluoromethyl-d-tyrosine as a radiotracer for tumor imaging with positron emission tomography. Nucl Med Biol, 2009. 36(3): p. 295-303.
56. Tomiyoshi, K., K. Amed, S. Muhammad, T. Higuchi, T. Inoue, K. Endo, and D. Yang, Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2-and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun, 1997. 18(2): p. 169-75.
57. Watanabe, H., T. Inoue, T. Shinozaki, T. Yanagawa, A.R. Ahmed, K. Tomiyoshi, N. Oriuchi, M. Tokunaga, J. Aoki, K. Endo, and K. Takagishi, PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med, 2000. 27(10): p. 1509-17.
58. Miyakubo, M., N. Oriuchi, Y. Tsushima, T. Higuchi, K. Koyama, K. Arai, B. Paudyal, Y. Iida, H. Hanaoka, T. Ishikita, Y. Nakasone, A. Negishi, K. Mogi, and K. Endo, Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha- methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med, 2007. 21(2): p. 129-35.
59. Miyashita, G., T. Higuchi, N. Oriuchi, Y. Arisaka, H. Hanaoka, H. Tominaga, S. Morita, M. Miyakubo, T. Ishikita, Y. Nakasone, A. Negishi, S. Yokoo, and K. Endo, (1)F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with (1)F-FDG PET and immunohistochemistry. Ann Nucl Med. 24(8): p. 579-84.
60. Kaira, K., N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, K. Dobashi, Y. Kanai, H. Endou, T. Nakajima, K. Endo, and M. Mori, Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res, 2007. 13(21): p. 6369-78.
61. Kaira, K., N. Oriuchi, K. Shimizu, H. Imai, H. Tominaga, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, Y. Kanai, T. Oyama, M. Mori, and K. Endo, Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 37(8): p. 911-6.
62. Kaira, K., N. Oriuchi, K. Shimizu, T. Ishikita, T. Higuchi, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, Y. Kanai, H. Endou, T. Nakajima, K. Endo, and M. Mori, Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci, 2009. 100(4): p. 753-8.
63. Wester, H.J., M. Herz, W. Weber, P. Heiss, R. Senekowitsch-Schmidtke, M. Schwaiger, and G. Stocklin, Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med, 1999. 40(1): p. 205-12.
64. Hamacher, K. and H.H. Coenen, Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot, 2002. 57(6): p. 853-6.
65. Krasikova, R.N., O.F. Kuznetsova, O.S. Fedorova, V.I. Maleev, T.F. Saveleva, and Y.N. Belokon, No carrier added synthesis of O-(2'-[18F] fluoroethyl)-L-tyrosine via a novel type of chiral enantiomerically pure precursor, NiII complex of a (S)-tyrosine Schiff base. Bioorg Med Chem, 2008. 16(9): p. 4994-5003.
66. Weber, W.A., H.J. Wester, A.L. Grosu, M. Herz, B. Dzewas, H.J. Feldmann, M. Molls, G. Stocklin, and M. Schwaiger, O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med, 2000. 27(5): p. 542-9.
67. Stober, B., U. Tanase, M. Herz, C. Seidl, M. Schwaiger, and R. Senekowitsch-Schmidtke, Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L- tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging, 2006. 33(8): p. 932-9.
68. Rau, F.C., W.A. Weber, H.J. Wester, M. Herz, I. Becker, A. Kruger, M. Schwaiger, and R. Senekowitsch-Schmidtke, O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging, 2002. 29(8): p. 1039-46.
69. Popperl, G., C. Gotz, W. Rachinger, F.J. Gildehaus, J.C. Tonn, and K. Tatsch, Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging, 2004. 31(11): p. 1464-70.
70. Plotkin, M., C. Blechschmidt, G. Auf, F. Nyuyki, L. Geworski, T. Denecke, W. Brenner, and F. Stockhammer, Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. 20(10): p. 2496-502.
71. Rachinger, W., C. Goetz, G. Popperl, F.J. Gildehaus, F.W. Kreth, M. Holtmannspotter, J. Herms, W. Koch, K. Tatsch, and J.C. Tonn, Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery, 2005. 57(3): p. 505-11; discussion 505-11.
72. Floeth, F.W., D. Pauleit, H.J. Wittsack, K.J. Langen, G. Reifenberger, K. Hamacher, M. Messing-Junger, K. Zilles, F. Weber, W. Stummer, H.J. Steiger, G. Woebker, H.W. Muller, H. Coenen, and M. Sabel, Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg, 2005. 102(2): p. 318-27.
73. Mehrkens, J.H., G. Popperl, W. Rachinger, J. Herms, K. Seelos, K. Tatsch, J.C. Tonn, and F.W. Kreth, The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol, 2008. 88(1): p. 27-35.
74. Hutterer, M., M. Nowosielski, D. Putzer, D. Waitz, G. Tinkhauser, H. Kostron, A. Muigg, I.J. Virgolini, W. Staffen, E. Trinka, T. Gotwald, A.H. Jacobs, and G. Stockhammer, O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma. J Nucl Med. 52(6): p. 856-64.
75. Floeth, F.W., D. Pauleit, M. Sabel, G. Stoffels, G. Reifenberger, M.J. Riemenschneider, P. Jansen, H.H. Coenen, H.J. Steiger, and K.J. Langen, Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med, 2007. 48(4): p. 519-27.
76. Thiele, F., J. Ehmer, M.D. Piroth, M.J. Eble, H.H. Coenen, H.J. Kaiser, W.M. Schaefer, U. Buell, and C. Boy, The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma. Phys Med Biol, 2009. 54(18): p. 5525-39.
77. Pauleit, D., G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H.H. Coenen, and K.J. Langen, PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. J Nucl Med, 2005. 46(3): p. 411-6.
78. Balogova, S., S. Perie, K. Kerrou, D. Grahek, F. Montravers, B. Angelard, B. Susini, P. El Chater, J.L. St Guily, and J.N. Talbot, Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Mol Imaging Biol, 2008. 10(6): p. 364-73.
79. Pauleit, D., A. Zimmermann, G. Stoffels, D. Bauer, J. Risse, M.O. Fluss, K. Hamacher, H.H. Coenen, and K.J. Langen, 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med, 2006. 47(2): p. 256-61.
80. Kuwabara, H., P. Cumming, J. Reith, G. Leger, M. Diksic, A.C. Evans, and A. Gjedde, Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab, 1993. 13(1): p. 43-56.
81. Chen, W., D.H. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy, 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med, 2006. 47(6): p. 904-11.
82. Hoegerle, S., C. Altehoefer, N. Ghanem, I. Brink, E. Moser, and E. Nitzsche, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med, 2001. 28(1): p. 64-71.
83. Koopmans, K.P., E.G. de Vries, I.P. Kema, P.H. Elsinga, O.C. Neels, W.J. Sluiter, A.N. van der Horst-Schrivers, and P.L. Jager, Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol, 2006. 7(9): p. 728-34.
84. Clavien, P.A., M. Schiesser, P. Veit-Haibach, M.K. Muller, M. Weber, P. Bauerfeind, and T. Hany, Value of combined 6-[(18)F]fluorodihydro- xyphenylalanine PET/CT for imaging of neuroendocrine tumours. British Journal of Surgery, 2010. 97(5): p. 691-697.
85. Jager, P.L., R. Chirakal, C.J. Marriott, A.H. Brouwers, K.P. Koopmans, and K.Y. Gulenchyn, 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med, 2008. 49(4): p. 573-86.
86. de Vries, E.F.J., G. Luurtsema, M. Brussermann, P.H. Elsinga, and W. Vaalburg, Fully automated synthesis module for the high yield one-pot preparation of 6-[F-18]fluoro-L-DOPA. Applied Radiation and Isotopes, 1999. 51(4): p. 389-394.
87. Langen, K.J., D. Pauleit, and H.H. Coenen, 3-[(123)I]Iodo-alpha-methyl-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol, 2002. 29(6): p. 625-31.
88. Kawai, K., Y. Fujibayashi, H. Saji, Y. Yonekura, J. Konishi, A. Kubodera, and A. Yokoyama, A strategy for the study of cerebral amino acid transport using iodine-123-labeled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L- tyrosine. J Nucl Med, 1991. 32(5): p. 819-24.
89. Jager, P.L., E.J. Franssen, W. Kool, B.G. Szabo, H.J. Hoekstra, H.J. Groen, E.G. de Vries, G.W. van Imhoff, W. Vaalburg, and D.A. Piers, Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors. J Nucl Med, 1998. 39(10): p. 1736-43.
90. Schmidt, D., K.J. Langen, H. Herzog, J. Wirths, M. Holschbach, J.C. Kiwit, K. Ziemons, H.H. Coenen, and H. Muller-Gartner, Whole-body kinetics and dosimetry of L-3-123I-iodo-alpha-methyltyrosine. Eur J Nucl Med, 1997. 24(9): p. 1162-6.
91. Grosu, A.L., W. Weber, H.J. Feldmann, B. Wuttke, P. Bartenstein, M.W. Gross, C. Lumenta, M. Schwaiger, and M. Molls, First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys, 2000. 47(2): p. 517-26.
92. Grosu, A.L., W.A. Weber, M. Franz, S. Stark, M. Piert, R. Thamm, H. Gumprecht, M. Schwaiger, M. Molls, and C. Nieder, Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys, 2005. 63(2): p. 511-9.
93. Kuwert, T., B. Woesler, C. Morgenroth, H. Lerch, M. Schafers, S. Palkovic, P. Matheja, W. Brandau, H. Wassmann, and O. Schober, Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med, 1998. 39(1): p. 23-7.
94. Jager, P.L., H.J. Groen, A. van der Leest, J.W. van Putten, R.M. Pieterman, E.G. de Vries, and D.A. Piers, L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations. J Nucl Med, 2001. 42(4): p. 579-85.
95. Flamen, P., N. Bernheim, P. Deron, V. Caveliers, K. Chavatte, P.R. Franken, and A. Bossuyt, Iodine-123 alpha-methyl-l-tyrosine single-photon emission tomography for the visualization of head and neck squamous cell carcinomas. Eur J Nucl Med, 1998. 25(2): p. 177-81.
96. Boni, R., H. Steinert, R. Huch Boni, G.K. Vo n Schulthess, J. Meyer, R. Dummer, G. Burg, and G. Westera, Radioiodine-labelled alpha-methyl-tyrosine in malignant melanoma: cell culture studies and results in patients. Br J Dermatol, 1997. 137(1): p. 96-100.
97. Jager, P.L., B.E. Plaat, E.G. de Vries, W.M. Molenaar, W. Vaalburg, D.A. Piers, and H.J. Hoekstra, Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res, 2000. 6(6): p. 2252-9.
98. Plotkin, M., R. Wurm, D. Kuczer, P. Wust, R. Michel, T. Denecke, J. Ruf, L. Schlenger, A. Bischoff, R. Felix, and H. Amthauer, Diagnostic value of 123I-IMT SPECT in the follow-up of head and neck cancer. Onkologie, 2006. 29(4): p. 147-52.
99. Plotkin, M., R. Wurm, J. Eisenacher, K. Szerewicz, R. Michel, L. Schlenger, M. Pech, T. Denecke, D. Kuczer, A. Bischoff, R. Felix, and H. Amthauer, Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer. Eur Radiol, 2006. 16(2): p. 503-11.
100. Sharma, R., M. Tripathi, P. Panwar, K. Chuttani, A. Jaimini, S. Maitra, M.K. Chopra, K. Sawroop, G. Shukla, A. Mondal, and A. Mishra, 99mTc-methionine scintimammography in the evaluation of breast cancer. Nucl Med Commun, 2009. 30(5): p. 338-42.
101. Marzilli, L.G., M.G. Banaszczyk, L. Hansen, Z. Kuklenyik, R. Cini, and A. Taylor, Linking Deprotonation and Denticity of Chelate Ligands-Rhenium(V) Oxo Analogs of Tc-99m Radiopharmaceuticals Containing N2s2 Chelate Ligands. Inorganic Chemistry, 1994. 33(22): p. 4850-4860.
102. Ketring, A.R., D.E. Troutner, T.J. Hoffman, D.K. Stanton, W.A. Volkert, and R.A. Holmes, Biodistribution of lipophilic 99mTc complexes of cyclam derivatives. Int J Nucl Med Biol, 1984. 11(2): p. 113-9.
103. Troutner, D.E., J. Simon, A.R. Ketring, W. Volkert, and R.A. Holmes, Complexing of Tc-99m with cyclam: concise communication. J Nucl Med, 1980. 21(5): p. 443-8.
104. Kong, F.L., Y. Zhang, M.S. Ali, C. Oh, R. Mendez, S. Kohanim, N. Tsao, M. Chanda, W.C. Huang, and D.J. Yang, Synthesis of (99m)Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer. Nucl Med Commun, 2010. 31(8): p. 699-707.
105. Kong, F.L., M.S. Ali, Y. Zhang, C.S. Oh, D.F. Yu, M. Chanda, and D.J. Yang, Synthesis and evaluation of amino acid-based radiotracer 99mTc-N4-AMT for breast cancer imaging. J Biomed Biotechnol, 2011. 2011: p. 276907.